← Back to Search

Anti-metabolites

Treatment arm for Arterial Restenosis

N/A
Waitlist Available
Led By Kong Teng Tan, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months post index procedure
Awards & highlights
No Placebo-Only Group

Summary

The purpose of the study is to evaluate the safety and efficacy on the use of drug eluting balloon (DEB) with paclitaxel to treat in-stent restenosis in femoropopliteal arteries.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months post index procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months post index procedure for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Target lesion patency at 6-month follow-up.
Secondary study objectives
Clinical success up to 12 months post index procedure

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Active Control
Group I: Treatment armActive Control1 Intervention
SFA angioplasty with In.Pact Admiral drug eluting balloon

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,520 Previous Clinical Trials
503,214 Total Patients Enrolled
Kong Teng Tan, MDPrincipal InvestigatorUniversity Health Network, Toronto
3 Previous Clinical Trials
50 Total Patients Enrolled
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top